AbbVie to acquire ImmunoGen to strengthen position in cancer therapies
AbbVie, a global biopharmaceutical company, has announced a groundbreaking $10.1 billion acquisition of ImmunoGen, a move that underscores the increasing interest of major drugmakers in [more…]
